Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus

Rina Mina, Marisa S. Klein-Gitelman, Shannen Nelson, B. Anne Eberhard, Gloria Higgins, Nora G. Singer, Karen Onel, Lori Tucker, Kathleen M. O'Neil, Marilynn Punaro, Deborah M. Levy, Kathleen Haines, Alberto Martini, Nicolino Ruperto, Daniel Lovell, Hermine I. Brunner

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Objectives: This study tested the concurrent validity of the systemic lupus erythematosus responder index (SRI) in assessing improvement in juvenile-onset systemic lupus erythematosus (jSLE). Methods: The SRI considers changes in the SELENA-SLEDAI, BILAG and a 3-cm visual analogue scale of physician-rated disease activity (PGA) to determine patient improvement. Using prospectively collected data from 760 unique follow-up visit intervals of 274 jSLE patients, we assessed the sensitivity and specificity of the SRI using these external standards: physician-rated improvement (MD-change), patient/parent-rated major improvement of wellbeing (patient-change) and decrease in prescribed systemic corticosteroids (steroid-change). Modifications of the SRI that considered different thresholds for the SELENA-SLEDAI, BILAG and 10-cm PGA were explored and agreement with the American College of Rheumatology/PRINTO provisional criteria for improvement of jSLE (PCI) was examined. Results: The sensitivity/specificity in capturing major improvement by the MD-change were 78%/76% for the SRI and 83%/78% for the PCI, respectively. There was fair agreement between the SRI and PCI (kappa=0.35, 95% CI 0.02 to 0.73) in capturing major improvement by the MD-change. Select modified versions of the SRI had improved accuracy overall. All improvement criteria tested had lower sensitivity when considering patientchange and steroid-change as external standards compared to MD-change. Conclusions: The SRI and its modified versions based on meaningful changes in jSLE have high specificity but at most modest sensitivity for capturing jSLE improvement. When used as an endpoint of clinical trials in jSLE, the SRI will provide a conservative estimate regarding the efficacy of the therapeutic agent under investigation.

Original languageEnglish (US)
Pages (from-to)401-406
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume73
Issue number2
DOIs
StatePublished - Feb 1 2014

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus'. Together they form a unique fingerprint.

  • Cite this

    Mina, R., Klein-Gitelman, M. S., Nelson, S., Anne Eberhard, B., Higgins, G., Singer, N. G., Onel, K., Tucker, L., O'Neil, K. M., Punaro, M., Levy, D. M., Haines, K., Martini, A., Ruperto, N., Lovell, D., & Brunner, H. I. (2014). Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. Annals of the Rheumatic Diseases, 73(2), 401-406. https://doi.org/10.1136/annrheumdis-2012-202376